[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-fibrosis":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,74,98,129,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":45,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100647234","phase-1-fapi-pet-imaging---an-exploratory-study-100647234",false,"NCT07705074","FAPI PET Imaging - An Exploratory Study","FAPI PET Imaging - a Multicentric Exploratory Evaluation","FAPIPET","Inclusion Criteria:\n\n* Written informed consent obtained and documented by the participant's signature.\n* Age ≥18 years at the time of consent.\n* Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.\n* Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT\u002FMRI) to allow comparative evaluation.\n\nExclusion Criteria:\n\n* Severe claustrophobia that would preclude PET imaging.\n* Inability to remain still for the duration of the PET\u002FMR examination.\n* Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.\n* Previous hypersensitivity reactions to radiotracer administration\n* Inability to understand the study information, for example due to language barriers.\n* Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).\n* Participants scheduled for PET\u002FMR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.","ALL","18 Years",{"count":20,"type":21},770,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study is testing a new imaging tracer called \\[18F\\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.\n\n\\[18F\\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.\n\nPeople who join this study will get one injection of the tracer into a vein, then have one PET\u002FCT or PET\u002FMR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.\n\nThe study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Thyroid Pathology","Head and Neck Cancer (H&N)","Sinonasal Tract Tumor","Sarcoidosis","Thyroid Cancer","Breast Cancer","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)","Pancreatic Cancer, Adult","Urothelial Carcinoma (UC)","Multiple Myeloma or Plasmacytoma","Mesothelioma","Hepatic Fibrosis","Endometriosis (Diagnosis)","Lung Fibrosis","Neck Node Metastasis","Prostate Cancer (CRPC)",[46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"[18F]FAPI-74","Fibroblast Activation Protein","FAP-targeted imaging","PET\u002FCT","Radiotracer","Diagnostic imaging","Multicentric study","Radiopharmaceutical","FAPI","FAPI-74","nuclear medicine","University Hospital Zurich","swiss multicenter trial","Cancer-associated fibroblast imaging","oncologic imaging","non-oncologic imaging","NOT_YET_RECRUITING","2026-07-09",{"date":65,"type":66},"2026-07-15","ACTUAL",{"date":68,"type":21},"2026-08",{"date":70,"type":21},"2029-09",{"name":72,"class":73},"Martin Huellner","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100525304","screening-for-advanced-liver-fibrosis-using-non-invasive-tests-in-primary-care-100525304","NCT06119997","Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care","ANTICIP-SP","Inclusion Criteria:\n\n* Patients between 18 and 70 years of age\n* FIB-4 2.67\n* Patients covered by Health Insurance System\n\nExclusion Criteria:\n\n* Prescription triggering FIB-4 emanate from a hepatogastroenterologist or oncologist\n* Conditions associated with high risk false-positive FIB-4: ASAT or ALAT \\> 300 IU\u002FL, platelets \\\u003C50 G\u002FL or \\>500 G\u002FL.\n* Patient refusing to participate\n* Subjects under guardianship or deprived of liberty","70 Years",{"count":83,"type":21},500,"OBSERVATIONAL","Liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. It is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (FIB-4).\n\nGiven this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis",[40],"RECRUITING","2026-05-18",{"date":90,"type":66},"2026-05-20",{"date":92,"type":66},"2025-06-26",{"date":94,"type":21},"2028-07-30",{"name":96,"class":73},"University Hospital, Grenoble",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":97},"100562188","phase-2-study-of-the-efficacy-and-safety-of-nicotinamide-in-patients-with-liver-fibrosis-nicofib-100562188","NCT06599918","Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)","Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Nicotinamide in Patients With and Liver Fibrosis (NICOFIB)","NICOFIB","Inclusion Criteria:\n\n* Patients aged between 18 and 85 years.\n* Diagnosis of non-alcoholic fatty liver disease (NAFLD) by their referring physicians (NAFLD defined as the presence of hepatic steatosis and in the absence of significant alcohol consumption, having excluded other liver diseases).\n* BMI between 27-40 kg\u002Fm2.\n* Fibroscan® value greater than 9.2 kPa, obtained within the last 6 months prior to the start of the study.\n\nExclusion Criteria:\n\n* Patients with any medical condition or illness that, in the opinion of the investigator, could interfere with the study results and\u002For affect the patients' ability to participate or complete the study.\n* History of clinically significant heart disease (ejection fraction \\\u003C40% \\[normal range 50-70%\\], heart failure defined as New York Heart Association \\[NYHA\\] Class \\> 2; clinically significant congenital or acquired valvular disease; symptomatic coronary artery disease such as myocardial infarction or angina, history of unstable arrhythmias, history of atrial fibrillation).\n* Decreased renal function (estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73 m2, calculated using the CKD-EPI formula) at screening.\n* Alcohol consumption exceeding 30 g\u002Fday in men or 20 g\u002Fday in women.\n* Patients with significant impairment of liver function in the selection analysis defined as repeated values of AST, ALT, and bilirubin \\> 3 times the upper limit of normal.\n* Positive for hepatitis B surface antigen or hepatitis C antibodies.\n* Patients with hepatocellular carcinoma.\n* Patients with liver cirrhosis (Fibroscan® \\> 18, compatible biopsy, or those who have experienced decompensations of cirrhosis).\n* Patients diagnosed with human immunodeficiency virus (HIV).\n* Patients with hypersensitivity or a history of severe allergies to NAM or excipients used in the preparation of capsules (NAM and placebo).\n* Patients with iodinated contrast allergy.\n* History or evidence of an autoimmune disorder considered clinically significant by the investigator or requiring systemic, chronic use of systemic corticosteroids or other immunosuppressants.\n* Patients on treatment with hepatotoxic drugs (amiodarone, immunosuppressants, ART, antituberculosis drugs, corticosteroids, etc.).\n* Patients consuming narcotic and psychotropic substances with hepatotoxic effects.\n* Individuals with incapacitating diseases or cognitive impairment.\n* Institutionalized patients or those without a fixed address.\n* Principal investigator's discretion in case of indications of low adherence to the trial or follow-up visits.\n* Individuals with a life expectancy of less than 12 months.\n* Patients participating in another interventional clinical trial, excluding observational\u002Fnatural history studies, at the start of the study or within the last 30 days before the start of the study.\n* Previous use of vitamin B3 (NAM), with abstinence required for at least 3 months before screening.\n* Pregnant women as determined by a positive high-sensitivity serum or urine pregnancy test (minimum sensitivity of 25 IU\u002FL or equivalent units of hCG) within 24 hours prior to screening, dosing, or completion of the study. Women of childbearing potential (WOCBP) will undergo a pregnancy test (serum or urine) 24 hours prior to screening, dosing, or completion of the study. Such participants must use a highly effective contraceptive method, such as combined hormonal contraceptives or intrauterine device (IUD), in accordance with the Clinical Trial Facilitation Group, throughout the entire study.\n* Breastfeeding women.\n* Patients undergoing treatment\u002Fsupplementation with vitamin E.\n* Patients receiving probiotics.\n* Patients on the waiting list for bariatric surgery in the next 12 months.\n* Patients undergoing treatment with drugs that may have an effect on the progression of liver disease.\n* Drugs for the treatment of T2DM with effects on NAFLD (GLP-1 analogs, thiazolidinediones such as pioglitazone) initiated within 6 months before the study start.\n* Drugs for the treatment of T2DM with effects on intestinal microbiota (metformin, α-GI inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) initiated within 6 months before the study start.\n* Patients who do not sign the informed consent.\n* Patients with contraindications to the contrast agent to be used in imaging tests.","85 Years",{"count":108,"type":21},30,[25],"The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.\n\nThe main question it aims to answer is:\n\n\\- To determine if the treatment with NAM is able to arrest, or even reduce, the hepatic fibrosis.\n\nIn addition, we also want to study the effect of NAM on:\n\n* General parameters (weight, HOMA-IR, etc).\n* Adiposity distribution (liver and body).\n* Systemic inflammation.\n* Thermogenic capacity of adipose tissue.\n* Microbiota composition.\n\nResearchers will compare NAM to a placebo, to see if NAM can arrest or revert hepatic fibrosis and its associated effects.\n\nParticipants will take either NAM or placebo. The dosage will be 1.2g\u002Fm2 NAM per day, for one year.",[112,113,40,114,115,116],"Fatty Liver","Obesity","NAFLD","Nicotinamide","Overweight and Obese Adults",[115,118,119],"Fatty liver","Nafld","2025-11-14",{"date":122,"type":66},"2025-11-18",{"date":124,"type":66},"2024-04-23",{"date":126,"type":21},"2028-12",{"name":128,"class":73},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100572916","efficacy-of-sodium-glucose-cotransporter-2-inhibitors-on-non-alcoholic-fatty-liver-disease-100572916","NCT06739486","Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* age \\>18 years\n* both sex\n\nExclusion Criteria:\n\n* alcohol drinker\n* any cause of liver affection (hepatitis, autoimmune…etc)\n* patients with kidney function affection","65 Years",{"count":137,"type":21},100,"evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease",[140,141,40,142],"Non Alcholic Fatty Liver Disease","Hepatic Steatosis","NAFLD (Nonalcoholic Fatty Liver Disease)",[114,144,145,146,147,148],"Non alcoholic fatty liver disease","Hepatic steatosis","Hepatic fibrosis","Na glucose cotransporter 2 inhibitors","SGLT-2 inhibitors","2024-12-17",{"date":151,"type":66},"2024-12-18",{"date":153,"type":21},"2024-12-20",{"date":155,"type":21},"2025-12-20",{"name":157,"class":73},"Assiut University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":165,"maxAge":135,"enrollmentInfo":166,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100571049","correlation-between-serum-adiponectin-and-resistin-levels-and-degree-of-hepatic-fibrosis-in-masld-with-type2-diabetes-mellitus-100571049","NCT06715189","Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus","Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus","Inclusion Criteria:\n\n* patients of both sex who have type2 Diabetes Mellitus for less than five years\n\nExclusion Criteria:alcholics ,chronic liver disease elevated liver functions , sever infection\n\n\\-","30 Years",{"count":167,"type":21},80,"Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus",[40],"2024-11-28",{"date":172,"type":66},"2024-12-04",{"date":174,"type":21},"2024-12-01",{"date":176,"type":21},"2025-12-30",{"name":178,"class":73},"Sohag University"]